NASDAQ:ELTX Elicio Therapeutics Q2 2025 Earnings Results & Report $1.84 +0.07 (+3.90%) As of 09:48 AM Eastern This is a fair market value price provided by Massive. Learn more. Elicio Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 7, 2025. The company reported EPS of -$0.66 versus the -$0.69 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 7, 2025TimeAfter Market ClosesConference Call4:00 PM ET Elicio Therapeutics EPS ResultsActual EPS-$0.66Consensus EPS -$0.69Beat/MissBeat by +$0.03One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersElicio Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsElicio Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Elicio Therapeutics Q2 2025 Earnings FAQ Did Elicio Therapeutics beat earnings estimates for Q2 2025? Elicio Therapeutics (NASDAQ:ELTX) reported earnings of -$0.66 per share for Q2 2025, beating the consensus estimate of -$0.69. The report was announced on Thursday, August 7, 2025. When is Elicio Therapeutics' next earnings date? Elicio Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Elicio Therapeutics on the company's earnings history page. Elicio Therapeutics Earnings HeadlinesElicio Therapeutics consensus price target lowered by 31.67% to $13.94October 3, 2026 | msn.comB. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy RatingSeptember 25, 2026 | finance.yahoo.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 14 at 1:00 AM | Profits Run (Ad)Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026September 24, 2026 | globenewswire.comElicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from S&P Global BMI IndexSeptember 21, 2026 | marketscreener.comMElicio Therapeutics Sets Key 2026 Shareholder Proposal DeadlinesSeptember 14, 2026 | tipranks.comSee More Elicio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Elicio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elicio Therapeutics and other key companies, straight to your email. Email Address About Elicio TherapeuticsElicio Therapeutics (NASDAQ:ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to treat cancer by directing immune responses to the lymph nodes, where key immune cells are activated. The company’s technology is based on its Amphiphile platform, which is intended to improve the delivery and activity of therapeutic vaccines and other immune-modulating agents. Elicio’s lead program is ELI-002, an investigational therapeutic cancer vaccine designed to target common KRAS mutations. The program is being evaluated in patients with KRAS-mutated solid tumors, including pancreatic and colorectal cancers. ELI-002 is intended to stimulate T-cell responses against residual disease and tumor cells carrying these mutations. The company is also advancing additional vaccine-based immunotherapies aimed at cancer-associated targets and personalized tumor antigens. Elicio Therapeutics was formerly known as Vedantra Pharmaceuticals and has focused on developing therapies intended to harness the immune system against cancer. Its products remain investigational and are not approved for commercial use.View Elicio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
